

Ortho Regenerative Technologies Inc. Announces CFO Change

KIRKLAND, Quebec, Aug. 31, 2018 -- Ortho Regenerative Technologies Inc. (CSE: ORTH) ("Ortho RTi" or the "Corporation") announces that Benedek (Ben) Simo has been appointed Interim Chief Financial Officer, effective immediately. Mr. Simo succeeds Jo-Anne Piché who is leaving the Corporation to pursue other professional projects.

"Jo-Anne has made many contributions to the Corporation and we wish her all the best in her future endeavors," said Ortho RTi's Executive Chairman and CEO, Dr. Brent Norton. "At the same time, we are excited to have attracted an executive of Ben's caliber to this position. With his depth of financial experience and proven track record of driving value in financial management, we believe that Ben is ideally suited to serve in this role."

Mr. Simo has over 15 years of experience in financial management with both private and public companies across a variety of sectors. Most recently, he was Manager, Financial Reporting at Resolute Forest Products, a NYSE- and TSX-listed global leader in the forest products industry with approximately US\$3.5 billion in annual revenues. Prior to that, he served as Financial Controller at Synchronica Inc, an AIM- and TSX-Venture Exchange-listed developer of next-generation mobile messaging solutions that was acquired by Myriad Group AG in 2012. Previously, Mr. Simo held financial management positions at TouchTunes Interactive Networks, McCain Foods Limited and Ipex Group. Mr. Simo earned a bachelor's degree in economics from McGill University, his MBA from Saint Mary's University, and has obtained a CPA auditor, CA designation.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Caution regarding forward-looking statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further information, please contact:

Stephen Kilmer
Investor & Media Relations
647.872.4849
kilmer@orthorti.com